Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-21, Stock:NVS, The news for the past five days is as follows:
2019-05-14: NEWS1: Ionis Pharmaceuticals Is 40% of the Way There.NEWS2: Ionis Pharmaceuticals Is 40% of the Way There.NEWS3: Ionis Pharmaceuticals Is 40% of the Way There.NEWS4: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.NEWS5: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.NEWS6: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS7: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS8: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS9: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.
2019-05-15: NEWS1: Teva Hits Fibonacci Support on Concerns Over Lawsuit.NEWS2: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS3: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS4: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS5: Novartis gets approval to sell Kymriah in Japan for $306,000.
2019-05-16: NEWS1: Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed.NEWS2: Three Conservative Ways to Play Cannabis.
2019-05-17: NEWS1: Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock.NEWS2: Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model.NEWS3: Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure.NEWS4: Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure.NEWS5: GSK and Novartis liniment marketing misled Australian consumers - court.
2019-05-20: NEWS1: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS2: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS3: Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study.NEWS4: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS5: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS6: Ligand Grants Preclinical Candidate Rights to UK-based Firm.NEWS7: Ligand Grants Preclinical Candidate Rights to UK-based Firm.NEWS8: 3 Ways to Buy Into the Marijuana Boom Without the Risk.NEWS9: Ligand Grants Preclinical Candidate Rights to UK-based Firm.

Answer: Rise